SCHEMBL19681680

SCHEMBL19681680

CC(C)C1CNC2Cn3cc(C(=O)NCc4ccc(F)cc4)c(=O)c(OCc4ccccc4)c3C(=O)N2C1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
MAPT P10636 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SGMS2 Q8NHU3 1/20 0.36
OPRL1 P41146 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PLA2G1B P04054 1/20 0.35
ATG4B Q9Y4P1 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35
TRPA1 O75762 1/20 0.34
SLC22A2 O15244 2/20 0.34
CNR2 P34972 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13601049 0.86 LMNA (0.47) LMNAMAPTL3MBTL1SGMS2ALDH1A1
SCHEMBL22605391 0.85 LMNA (0.46) LMNAMAPTL3MBTL1SGMS2ALDH1A1
SCHEMBL19334683 0.85 LMNA (0.45) LMNAMAPTL3MBTL1SGMS2OPRL1
SCHEMBL18881134 0.84 LMNA (0.42) LMNAMAPTL3MBTL1SGMS2ALDH1A1
SCHEMBL13601048 0.80 LMNA (0.44) LMNAMAPTL3MBTL1SGMS2ALDH1A1
SCHEMBL86291 0.80 MAPT (0.48) LMNAMAPTL3MBTL1SGMS2ALDH1A1
SCHEMBL17005327 0.80 LMNA (0.48) LMNAMAPTL3MBTL1SGMS2ALDH1A1
SCHEMBL13601051 0.79 LMNA (0.46) LMNAMAPTL3MBTL1SGMS2ALDH1A1
SCHEMBL22584735 0.79 LMNA (0.43) LMNAMAPTL3MBTL1SGMS2ALDH1A1
SCHEMBL19348145 0.79 LMNA (0.47) LMNAMAPTL3MBTL1SGMS2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202379-B2 Substituted polycyclic carbamoyl pyridone derivative prodrug SHIONOGI & CO., LTD. (JP) 2019-02-12 US disclosed
US-20170349587-A1 SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG SHIONOGI & CO., LTD. (JP) 2017-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349587-A1 SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG PREP, UNG, DPP4 LMNA 1238/4885MAPT 4568/4885L3MBTL1 2179/4885
US-10202379-B2 Substituted polycyclic carbamoyl pyridone derivative prodrug PREP, UNG, DPP4 LMNA 1238/4885MAPT 4568/4885L3MBTL1 2179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.